Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 Apr 20. doi: 10.1038/s41416-018-0064-3. [Epub ahead of print]

PMID:
29674707
2.

Comparative methylome analysis of ICF patients identifies heterochromatin loci that require ZBTB24, CDCA7 and HELLS for their methylated state.

Velasco G, Grillo G, Touleimat N, Ferry L, Ivkovic I, Ribierre F, Deleuze JF, Chantalat S, Picard C, Francastel C.

Hum Mol Genet. 2018 Apr 12. doi: 10.1093/hmg/ddy130. [Epub ahead of print]

PMID:
29659838
3.

Matriptase-2 deficiency protects from obesity by modulating iron homeostasis.

Folgueras AR, Freitas-Rodríguez S, Ramsay AJ, Garabaya C, Rodríguez F, Velasco G, López-Otín C.

Nat Commun. 2018 Apr 10;9(1):1350. doi: 10.1038/s41467-018-03853-1.

4.

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.

Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G.

Oncotarget. 2018 Jan 20;9(9):8706-8715. doi: 10.18632/oncotarget.24283. eCollection 2018 Feb 2.

5.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

PMID:
29437040
6.

The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.

Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, Choueiri TK, McKay RR.

Clin Genitourin Cancer. 2018 Apr;16(2):e327-e333. doi: 10.1016/j.clgc.2017.11.005. Epub 2017 Dec 6.

PMID:
29361425
7.

Cancer Susceptibility Models in Protease-Deficient Mice.

Folgueras AR, Freitas-Rodríguez S, Español Y, Velasco G.

Methods Mol Biol. 2018;1731:235-245. doi: 10.1007/978-1-4939-7595-2_21.

PMID:
29318558
8.

The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort.

Sun M, De Velasco G, Brastianos PK, Aizer AA, Martin A, Moreira R, Nguyen PL, Trinh QD, Choueiri TK.

Eur Urol Focus. 2018 Jan 5. pii: S2405-4569(17)30294-8. doi: 10.1016/j.euf.2017.12.007. [Epub ahead of print]

PMID:
29311016
9.

Urothelial cancer proteomics provides both prognostic and functional information.

de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sepúlveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D.

Sci Rep. 2017 Nov 17;7(1):15819. doi: 10.1038/s41598-017-15920-6.

10.

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.

Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA.

Oncotarget. 2017 Aug 8;8(48):84572-84578. doi: 10.18632/oncotarget.20028. eCollection 2017 Oct 13. Review.

11.

Adaptive Evolution under Extreme Genetic Drift in Oxidatively Stressed Caenorhabditis elegans.

Christy SF, Wernick RI, Lue MJ, Velasco G, Howe DK, Denver DR, Estes S.

Genome Biol Evol. 2017 Nov 1;9(11):3008-3022. doi: 10.1093/gbe/evx222.

12.

In Reply.

de Velasco G, Culhane AC, Heng DYC, Signoretti S, Choueiri TK.

Oncologist. 2017 Dec;22(12):1561. doi: 10.1634/theoncologist.2017-0283. Epub 2017 Sep 11. No abstract available.

13.

TMJ symptoms reduce chewing amplitude and velocity, and increase variability.

Radke JC, Kamyszek GJ, Kull RS, Velasco GR.

Cranio. 2017 Sep 4:1-8. doi: 10.1080/08869634.2017.1365421. [Epub ahead of print]

PMID:
28868987
14.

Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.

Sevillano E, Werner L, Bossé D, Lalani AA, Wankowicz SAM, de Velasco G, Farina M, Lundgren K, Choueiri TK, González Del Alba A, Bellmunt J.

Clin Genitourin Cancer. 2017 Dec;15(6):e1089-e1094. doi: 10.1016/j.clgc.2017.07.012. Epub 2017 Aug 2.

PMID:
28864222
15.

TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.

Gaweł-Bęben K, Ali N, Ellis V, Velasco G, Poghosyan Z, Ager A, Knäuper V.

Cell Biol Int. 2018 Mar;42(3):273-280. doi: 10.1002/cbin.10832. Epub 2017 Aug 21.

16.

Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.

de Velasco G, Gray KP, Hamieh L, Urun Y, Carol HA, Fay AP, Signoretti S, Kwiatkowski DJ, McDermott DF, Freedman M, Pomerantz MM, Choueiri TK.

Eur Urol Focus. 2016 Dec 15;2(6):633-639. doi: 10.1016/j.euf.2016.03.017. Epub 2016 Apr 23.

17.

Erratum: The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.

Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-Martin M, Fernández-Ruiz S, Morciano G, Caro-Maldonado A, Guiu M, Zúñiga-García P, Graupera M, Bellmunt A, Pandya P, Lorente M, Martín-Martín N, Sutherland JD, Sanchez-Mosquera P, Bozal-Basterra L, Zabala-Letona A, Arruabarrena-Aristorena A, Berenguer A, Embade N, Ugalde-Olano A, Lacasa-Viscasillas I, Loizaga-Iriarte A, Unda-Urzaiz M, Schultz N, Aransay AM, Sanz-Moreno V, Barrio R, Velasco G, Pinton P, Cordon-Cardo C, Locasale JW, Gomis RR, Carracedo A.

Nat Cell Biol. 2017 Jun 29;19(7):873. doi: 10.1038/ncb3558.

PMID:
28659639
18.

Angiopoietin-1 enhances neutrophil chemotaxis in vitro and migration in vivo through interaction with CD18 and release of CCL4.

Burnett A, Gomez I, De Leon DD, Ariaans M, Progias P, Kammerer RA, Velasco G, Marron M, Hellewell P, Ridger V.

Sci Rep. 2017 May 24;7(1):2332. doi: 10.1038/s41598-017-02216-y.

19.

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ.

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

PMID:
28528867
20.

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC.

Cancer Med. 2017 May;6(5):902-909. doi: 10.1002/cam4.1048. Epub 2017 Apr 16.

21.

Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.

de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.

PMID:
28410911
22.

Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment.

Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, Chang SL, Trinh QD, Choueiri TK.

Eur Urol. 2017 Aug;72(2):171-174. doi: 10.1016/j.eururo.2017.03.005. Epub 2017 Mar 27.

PMID:
28359734
23.

Biosimilar biologic drugs: a new frontier in medical care.

Geynisman DM, De Velasco G, Sewell KL, Jacobs I.

Postgrad Med. 2017 May;129(4):460-470. doi: 10.1080/00325481.2017.1311196. Epub 2017 Apr 3. Review.

PMID:
28343424
24.

ICF-specific DNMT3B dysfunction interferes with intragenic regulation of mRNA transcription and alternative splicing.

Gatto S, Gagliardi M, Franzese M, Leppert S, Papa M, Cammisa M, Grillo G, Velasco G, Francastel C, Toubiana S, D'Esposito M, Angelini C, Matarazzo MR.

Nucleic Acids Res. 2017 Jun 2;45(10):5739-5756. doi: 10.1093/nar/gkx163.

25.

Electrochemical oxidation of cyanide on 3D Ti-RuO2 anode using a filter-press electrolyzer.

Pérez T, López RL, Nava JL, Lázaro I, Velasco G, Cruz R, Rodríguez I.

Chemosphere. 2017 Jun;177:1-6. doi: 10.1016/j.chemosphere.2017.02.136. Epub 2017 Feb 28.

PMID:
28279900
26.

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.

De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK.

Clin Genitourin Cancer. 2017 Jun;15(3):403-410.e2. doi: 10.1016/j.clgc.2017.01.005. Epub 2017 Jan 12.

PMID:
28254206
27.

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2017 Mar 1;18(1):46. doi: 10.1186/s13059-017-1180-8. No abstract available.

28.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK.

Cancer Immunol Res. 2017 Apr;5(4):312-318. doi: 10.1158/2326-6066.CIR-16-0237. Epub 2017 Feb 28.

29.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

30.

CENP-A chromatin disassembly in stressed and senescent murine cells.

Hédouin S, Grillo G, Ivkovic I, Velasco G, Francastel C.

Sci Rep. 2017 Feb 10;7:42520. doi: 10.1038/srep42520.

31.

Telomeres in ICF syndrome cells are vulnerable to DNA damage due to elevated DNA:RNA hybrids.

Sagie S, Toubiana S, Hartono SR, Katzir H, Tzur-Gilat A, Havazelet S, Francastel C, Velasco G, Chédin F, Selig S.

Nat Commun. 2017 Jan 24;8:14015. doi: 10.1038/ncomms14015.

32.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

33.

Corrigendum to "The use of cannabinoids as anticancer agents" [Prog. Neuro-Psychopharmacol. Biol. Psychiatry 64 (2016) 259-266].

Velasco G, Hernández-Tiedra S, Dávila D, Lorente M.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Mar 6;74:57. doi: 10.1016/j.pnpbp.2016.12.005. No abstract available.

PMID:
28063470
34.

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2016 Nov 17;17(1):231. Erratum in: Genome Biol. 2017 Mar 1;18(1):46.

35.

The cannabinoid receptor CB1 contributes to the development of ectopic lesions in a mouse model of endometriosis.

Sanchez AM, Quattrone F, Pannese M, Ulisse A, Candiani M, Diaz-Alonso J, Velasco G, Panina-Bordignon P.

Hum Reprod. 2017 Jan;32(1):175-184. Epub 2016 Nov 7.

PMID:
27821707
36.

Loss of the Methyl-CpG-Binding Protein ZBTB4 Alters Mitotic Checkpoint, Increases Aneuploidy, and Promotes Tumorigenesis.

Roussel-Gervais A, Naciri I, Kirsh O, Kasprzyk L, Velasco G, Grillo G, Dubus P, Defossez PA.

Cancer Res. 2017 Jan 1;77(1):62-73. doi: 10.1158/0008-5472.CAN-16-1181. Epub 2016 Nov 4.

37.

Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization.

Hernández-Tiedra S, Fabriàs G, Dávila D, Salanueva ÍJ, Casas J, Montes LR, Antón Z, García-Taboada E, Salazar-Roa M, Lorente M, Nylandsted J, Armstrong J, López-Valero I, McKee CS, Serrano-Puebla A, García-López R, González-Martínez J, Abad JL, Hanada K, Boya P, Goñi F, Guzmán M, Lovat P, Jäättelä M, Alonso A, Velasco G.

Autophagy. 2016 Nov;12(11):2213-2229. Epub 2016 Sep 16.

38.

Human Atg8-cardiolipin interactions in mitophagy: Specific properties of LC3B, GABARAPL2 and GABARAP.

Antón Z, Landajuela A, Hervás JH, Montes LR, Hernández-Tiedra S, Velasco G, Goñi FM, Alonso A.

Autophagy. 2016 Dec;12(12):2386-2403. Epub 2016 Oct 20.

39.
40.

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK.

J Clin Oncol. 2016 Sep 6. pii: JCO667311. [Epub ahead of print]

41.

Competition between members of the tribbles pseudokinase protein family shapes their interactions with mitogen activated protein kinase pathways.

Guan H, Shuaib A, Leon DD, Angyal A, Salazar M, Velasco G, Holcombe M, Dower SK, Kiss-Toth E.

Sci Rep. 2016 Sep 7;6:32667. doi: 10.1038/srep32667.

42.

Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.

de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK.

Cancer Immunol Res. 2016 Oct;4(10):820-822. Epub 2016 Aug 18.

43.

Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK.

J Natl Compr Canc Netw. 2016 Jul;14(7):820-4.

44.

Novel LMNA mutations cause an aggressive atypical neonatal progeria without progerin accumulation.

Soria-Valles C, Carrero D, Gabau E, Velasco G, Quesada V, Bárcena C, Moens M, Fieggen K, Möhrcken S, Owens M, Puente DA, Asensio Ó, Loeys B, Pérez A, Benoit V, Wuyts W, Lévy N, Hennekam RC, De Sandre-Giovannoli A, López-Otín C.

J Med Genet. 2016 Jun 22. pii: jmedgenet-2015-103695. doi: 10.1136/jmedgenet-2015-103695. [Epub ahead of print]

PMID:
27334370
45.

Corrigendum: Mutations in CDCA7 and HELLS cause immunodeficiency-centromeric instability-facial anomalies syndrome.

Thijssen PE, Ito Y, Grillo G, Wang J, Velasco G, Nitta H, Unoki M, Yoshihara M, Suyama M, Sun Y, Lemmers RJ, de Greef JC, Gennery A, Picco P, Kloeckener-Gruissem B, Güngör T, Reisli I, Picard C, Kebaili K, Roquelaure B, Iwai T, Kondo I, Kubota T, van Ostaijen-Ten Dam MM, van Tol MJ, Weemaes C, Francastel C, van der Maarel SM, Sasaki H.

Nat Commun. 2016 Jun 22;7:12003. doi: 10.1038/ncomms12003. No abstract available.

46.

Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.

Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD, Choueiri TK.

J Clin Oncol. 2016 Sep 20;34(27):3267-75. doi: 10.1200/JCO.2016.66.7931. Epub 2016 Jun 20.

47.

TRIB3 suppresses tumorigenesis by controlling mTORC2/AKT/FOXO signaling.

Salazar M, Lorente M, García-Taboada E, Gómez EP, Dávila D, Zúñiga-García P, Flores JM, Rodríguez A, Hegedus Z, Mosén-Ansorena D, Aransay AM, Hernández-Tiedra S, López-Valero I, Quintanilla M, Sánchez C, Iovanna JL, Dusetti N, Guzmán M, Francis SE, Carracedo A, Kiss-Toth E, Velasco G.

Mol Cell Oncol. 2015 Apr 18;2(3):e980134. doi: 10.4161/23723556.2014.980134. eCollection 2015 Jul-Sep.

48.

Reproductive biology of the stingrays, Myliobatis goodei and Myliobatis ridens (Chondrichthyes: Myliobatidae), in southern Brazil.

Araújo PR, Oddone MC, Velasco G.

J Fish Biol. 2016 Jul;89(1):1043-67. doi: 10.1111/jfb.13015. Epub 2016 May 25.

PMID:
27221505
49.

The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.

Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-Martin M, Fernández-Ruiz S, Morciano G, Caro-Maldonado A, Guiu M, Zúñiga-García P, Graupera M, Bellmunt A, Pandya P, Lorente M, Martín-Martín N, Sutherland JD, Sanchez-Mosquera P, Bozal-Basterra L, Zabala-Letona A, Arruabarrena-Aristorena A, Berenguer A, Embade N, Ugalde-Olano A, Lacasa-Viscasillas I, Loizaga-Iriarte A, Unda-Urzaiz M, Schultz N, Aransay AM, Sanz-Moreno V, Barrio R, Velasco G, Pinton P, Cordon-Cardo C, Locasale JW, Gomis RR, Carracedo A.

Nat Cell Biol. 2016 Jun;18(6):645-656. doi: 10.1038/ncb3357. Epub 2016 May 23. Erratum in: Nat Cell Biol. 2017 Jun 29;19(7):873.

50.

A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.

McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK.

Cancer. 2016 Aug 1;122(15):2389-98. doi: 10.1002/cncr.30056. Epub 2016 May 19.

Supplemental Content

Loading ...
Support Center